Ontario agrees to pay for J&J's Zytiga pill; Lundbeck asks for EU nod on its new antidepressant;

 @FiercePharma: Bayer CEO tells Boston audience that pricing pressure threatens innovation--but U.S. isn't the problem. More | Follow @FiercePharma

> The Canadian state of Ontario has agreed to foot the bill for Johnson & Johnson's ($JNJ) new prostate cancer pill Zytiga. Report

> Lundbeck filed for European approval of its new antidepressant, with plans to file in the U.S. by year's end. Report

> FDA sent Jazz Pharmaceuticals a warning letter, saying that a patient brochure supporting the antipsychotic drug FazaClo was false or misleading because it left out or minimized the drug's risks and overstated its efficacy. Report

> The U.K.'s pharma industry trade group cleared Sanofi ($SNY) of wrongdoing after an ex-employee accused the French drugmaker of promoting drugs for off-label use, among other infractions. Report

> Free trade negotiations between Canada and the E.U. have bogged down in fears that extended patent protections could push up the costs of prescription drugs. Report

> Drug distributor Harvard Drug Group is buying an undisclosed generics manufacturer for $117 million, Standard & Poor's reports. Report

> Glenmark Pharmaceuticals won tentative FDA approval for its version of the Merck ($MRK) migraine treatment Maxalt. Report

Medical Device News

 @FierceMedDev: We are in the FMD Fierce 15 final stretch. Winners revealed on Oct. 2 at AdvaMed 2012 and in FMD. Innovators all. More | Follow @FierceMedDev

 @MarkHFierce: In Mass., Dx, Rx and device companies can now cover modest meals and drinks, thanks to relaxed gift ban regs. Story | Follow @MarkHFierce

 @DamianFierce: Seattle startup Innovative Pulmonary has a new CEO and $10.6M in financing. News | Follow @DamianFierce

> Survey: Pharmas value tech when choosing Dx partners. More

> Conflicting arguments abound on the device tax's merits. Item

> Given Imaging soars after filing for Japanese approval. Article

Biotech News

 @FierceBiotech: Slideshow: FierceBiotech's 2012 Fierce 15 at BioPharm America 2012. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Novartis grabs a $665M option to buy sickle cell disease biotech--Selexys who? Story | Follow @JohnCFierce

 @RyanMFierce: MacroGenics banks $20M in potential $1.1B cancer drugs deal with Servier. Article | Follow @RyanMFierce

> NYC coup: Roche picks Big Apple site for new R&D home. News

> Foundation Medicine hauls in $42.5M round to back commercialization effort. Story

> Third Rock bankrolls a new biotech to tackle genetic heart disease. News

Vaccines News

> Cardiff University works on anthrax vaccine for NATO. Item

> Emory snags $6M for HIV/AIDS vaccine research. Article

> Software magnate sinks $104M into vaccine research. More

> Obesity vaccine hits obstacle. Story

Pharma Manufacturing News

> Wholesaler McKesson faces new price-manipulation suit. Story

> Gerresheimer glass plant adds line, new furnace. Article

> Regulators OK Recipharm Monts filling expansion. More

> Florida man tied to cargo thefts ordered to forfeit $55M. News

And Finally... The Congressional Budget Office now estimates that 6 million Americans will pay the penalty for failing to buy health insurance, partly because of higher unemployment. Report

Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.